iView Therapeutics Inc has completed patient recruitment for its Phase 1/2 clinical trial (NCT06400459) evaluating IVW-1001 for the signs and symptoms of dry eye disease (DED). The Phase 1/2 trial ...
The report urges the US Department of Health and Human Services, in collaboration with departments of education at the state ...
According to the company, topline results will be presented at the 2024 American Academy of Ophthalmology Annual Meeting, ...
Unlocking the potential of donor scleral tissue: Innovations and future applications. When organs are donated, it is with the ...
The announcement marks the second FDA designation for ATSN-201, which previously received Rare Pediatric Disease designation.
The acquisition strengthens the company’s rare disease segment, and adds 2 durable commercial assets, Iluvien and Yutiq with ...
Diana Do, MD, spoke with the Ophthalmology Times team about her presentation at the Retina Society meeting focusing on Population Pharmacokinetic Modeling and Simulation of Ocular Clearance for ...
David A. Eichenbaum, MD, presented key data from two clinical trials focusing on therapies for age-related macular ...
Laura M. Periman, MD, shares her passion for dry eye disease, discussing her discovery of the Alpenglow Sign in Demodex ...
Researchers at the Karolinska Institute continue to investigate whether gene therapy can improve vision in people with ...
The American Society of Retina Specialists (ASRS) hosted its annual meeting July 17 to 20 in the Swedish capital city of ...
Durga Borkar, MD, sat down with Sydney Crago of Modern Retina to discuss one of her presentations on the first time phase 2 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback